Publications Office of the EU
Médicaments antinéoplasiques (ATC L01) et autres immunosuppresseurs (ATC L04AX) - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

Médicaments antinéoplasiques (ATC L01) et autres immunosuppresseurs (ATC L04AX)

Overview
  • Published
    24/02/2025
  • Today
    15/03/2025
  • Deadline
    25/03/2025
  • Opening of tenders
    25/03/2025
Status
Published
Type of contract
Supplies
Subject for Renewal
No
Buyer
Healthcare Public Procurement (HeCaPP)
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: BE100 Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Number of lots
8
Procedure details
Tender reference number
PPP0KC-2331/5243/HECAPP/2025/PO/MEDICAMENTS ANTINEOPLASIQUES
Description

Médicaments antinéoplasiques (ATC L01) et autres immunosuppresseurs (ATC L04AX)

Submission Method
Electronic via:
https://www.publicprocurement.be
Tenders may be submitted
Electronic submission: required
https://www.publicprocurement.be
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
25/03/2025 11:00
Place of performance
BE Belgique/België
BE100 Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
CPV code

33600000 - Pharmaceutical products

Lots (8)
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.